Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan

[Guest guest]

http://www.springerlink.com/content/w4x2564262jm190t/

Hepatology International

DOI: 10.1007/s12072-010-9248-5Online First™

Original Article

Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic

liver diseases in Taiwan

Yone-Han Mah, Ching-Sheng Hsu, Chen-Hua Liu, Chun-Jen Liu, Ming-Yang Lai,

Pei-Jer Chen, Ding-Shinn Chen and Jia-Horng Kao

Abstract

Background and aims

Polymorphisms of p53 gene are known to play an important role in

hepatocarcinogenesis. We aimed to investigate the impact of p53 polymorphisms on

disease progression by evaluating their prevalence among chronic hepatitis B

(CHB) or hepatitis C (CHC) patients with different stages of liver disease.

Methods

A total of 215 CHB, 108 CHC patients with different stages of liver disease and

49 healthy controls were consecutively enrolled. The codon 249 p53 mutations as

well as codon 72 polymorphisms were assayed by molecular methods, and their

prevalence among the enrolled subjects was evaluated.

Results

All patients and controls had codon 249 wild-type sequences. Among codon 72

sequences, Pro/Pro allele frequency of Hepatitis B-related HCC (31.4%),

cirrhosis (26.9%), HBV carriers (26.3%), hepatitis C-related cirrhosis (39.1%),

and CHC patients (24%) were higher than that of healthy controls (18.4%). After

adjustment for sex and age, codon 72 mutant and mixed type were associated with

a higher likelihood of asymptomatic carrier state than those with wild type in

CHB patients [odd ratio (OR): 2.53, 95% confidence interval (CI) 1.06–6.03, P =

0.037]. However, the prevalence of codon 72 mutant and mixed type were

comparable with wild type among CHC patients with HCC (OR 0.70, 95% CI

0.28–1.72, P = 0.433).

Conclusions

Although serum 249serine p53 mutation is rarely found in Taiwanese patients, HBV

carriers have a higher prevalence of codon 72 mutants than patients with much

severe liver diseases or HCV infection, which implies that codon 72 mutants may

affect at an earlier stage of HBV infection. Further studies are necessary to

delineate the interactions of p53 mutations with HBV infection.

[Guest guest]

http://www.springerlink.com/content/w4x2564262jm190t/

Hepatology International

DOI: 10.1007/s12072-010-9248-5Online First™

Original Article

Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic

liver diseases in Taiwan

Yone-Han Mah, Ching-Sheng Hsu, Chen-Hua Liu, Chun-Jen Liu, Ming-Yang Lai,

Pei-Jer Chen, Ding-Shinn Chen and Jia-Horng Kao

Abstract

Background and aims

Polymorphisms of p53 gene are known to play an important role in

hepatocarcinogenesis. We aimed to investigate the impact of p53 polymorphisms on

disease progression by evaluating their prevalence among chronic hepatitis B

(CHB) or hepatitis C (CHC) patients with different stages of liver disease.

Methods

A total of 215 CHB, 108 CHC patients with different stages of liver disease and

49 healthy controls were consecutively enrolled. The codon 249 p53 mutations as

well as codon 72 polymorphisms were assayed by molecular methods, and their

prevalence among the enrolled subjects was evaluated.

Results

All patients and controls had codon 249 wild-type sequences. Among codon 72

sequences, Pro/Pro allele frequency of Hepatitis B-related HCC (31.4%),

cirrhosis (26.9%), HBV carriers (26.3%), hepatitis C-related cirrhosis (39.1%),

and CHC patients (24%) were higher than that of healthy controls (18.4%). After

adjustment for sex and age, codon 72 mutant and mixed type were associated with

a higher likelihood of asymptomatic carrier state than those with wild type in

CHB patients [odd ratio (OR): 2.53, 95% confidence interval (CI) 1.06–6.03, P =

0.037]. However, the prevalence of codon 72 mutant and mixed type were

comparable with wild type among CHC patients with HCC (OR 0.70, 95% CI

0.28–1.72, P = 0.433).

Conclusions

Although serum 249serine p53 mutation is rarely found in Taiwanese patients, HBV

carriers have a higher prevalence of codon 72 mutants than patients with much

severe liver diseases or HCV infection, which implies that codon 72 mutants may

affect at an earlier stage of HBV infection. Further studies are necessary to

delineate the interactions of p53 mutations with HBV infection.